Grundlæggende statistik
| CIK | 1806952 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lyell Immunopharma, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| May 6, 2026 |
Exhibit 10.2 Lyell Immunopharma, Inc. Non-Employee Director Compensation Policy Adopted by the Board of Directors: November 11, 2019 Last Amended and Restated: April 9, 2026, to be effective June 10, 2026 Effective Date: June 10, 2026 Each member of the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) who is a non-employee director of the Company (each such member, an “ |
|
| May 6, 2026 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 •PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in 2027 •PiNACLE-H2H, a first of its kind Phase 3 c |
|
| April 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def |
|
| April 24, 2026 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t |
|
| April 24, 2026 |
(! '&''& &(% ' &!+!" && "! */@67;5A<; 999999999999999999999999999999999 "% 999999999999999999999999999999999 /?8";3 !!( %#"%'#(%&(!''"&' "! "% 2"'&(% ' & +!' " HKHMA>KCNKBL=BK%=>GMB?B<:MBHG*H /@87;@*/F &LLH?,KBG+??B<>L 6BI H=> . |
|
| April 13, 2026 |
LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 CORRESP LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 VIA EDGAR April 10, 2026 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes Re: Lyell Immunopharma, Inc. Registration Statement on Form S-3 File No. 333-294884 Acceleration Request Requested Date: April 14, 2 |
|
| April 8, 2026 |
April 8, 2026 Lynn Seely Chief Executive Officer Lyell Immunopharma, Inc. 201 Haskins Way South San Francisco, CA 94080 Re: Lyell Immunopharma, Inc. Registration Statement on Form S-3 Filed April 3, 2026 File No. 333-294884 Dear Lynn Seely: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accel |
|
| April 3, 2026 |
As filed with the Securities and Exchange Commission on April 3, 2026 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 3, 2026 Registration No. |
|
| April 3, 2026 |
Calculation of Filing Fee Tables S-3 Lyell Immunopharma, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In |
|
| March 12, 2026 |
Exhibit 10.25 CONFIDENTIAL EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT by and between LYELL IMMUNOPHARMA, INC. and INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LIMITED November 6, 2025 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of November 6, 2025 (the “Effective Date”), by and between Lyell Immunopharma, Inc., a Delaware corpor |
|
| March 12, 2026 |
As filed with the Securities and Exchange Commission on March 12, 2026 S-8 As filed with the Securities and Exchange Commission on March 12, 2026 Registration No. |
|
| March 12, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Lyell Immunopharma, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the Registrant's 2021 Equity In |
|
| March 12, 2026 |
Lyell Immunopharma, Inc. Insider Trading Policy Exhibit 19.1 Lyell Immunopharma, Inc. Insider Trading Policy Adopted by the Board of Directors: April 19, 2021 Last Amended by the Board of Directors: December 3, 2025 Introduction During the course of your relationship with Lyell Immunopharma, Inc. (“Lyell”), you may receive material information that is not yet publicly available (“material nonpublic information”) about Lyell or other publicly tr |
|
| March 12, 2026 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results •Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) evaluating ronde-cel is ongoing •Phase 1 trial is ongoing for LYL273, an enhanced GCC-targeted |
|
| March 12, 2026 |
Exhibit 10.7 Lyell Immunopharma, Inc. Non-Employee Director Compensation Policy Adopted by the Board of Directors: November 11, 2019 Last Amended and Restated: April 24, 2024, to be effective June 14, 2024 Effective Date: June 14, 2024 Each member of the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) who is a non-employee director of the Company (each such member, an |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-405 |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 12, 2026 |
Exhibit 10.3 Lyell Immunopharma, Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: JUNE 8, 2021 Approved by the Stockholders: June 15, 2021 (as adjusted for 1-for-20 reverse stock split, effective May 30, 2025) 1.GENERAL. (a)Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awar |
|
| March 12, 2026 |
Exhibit 10.6 Lyell Immunopharma, Inc. 2021 Employee Stock Purchase Plan Adopted by the Board of Directors: June 8, 2021 Approved by the Stockholders: June 15, 2021 IPO Date: June 16, 2021 (as adjusted for 1-for-20 reverse stock split, effective May 30, 2025) 1.General; Purpose. (a)The Plan provides a means by which Eligible Employees of the Company and Designated Companies may be given an opportun |
|
| March 12, 2026 |
Exhibit 10.24 EXECUTION VERSION CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT by and among LYELL IMMUNOPHARMA, INC., INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LIMITED and INNOVATIVE CELLULAR THERAPEUTICS, INC. EFFECTIVE DATE: November |
|
| March 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2026 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 9, 2026 |
EX-10.1 Exhibit 10.1 March 3, 2026 Smital Shah Electronic delivery Re: Offer of Employment by Lyell Immunopharma, Inc. Dear Smital, I am very pleased to confirm our offer to you of employment as Chief Financial and Business Officer at Lyell Immunopharma, Inc. (the “Company”). The opportunity to work with you to build one of the world’s great companies whose goal is nothing less than to develop cur |
|
| December 18, 2025 |
PROSPECTUS Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-291970 PROSPECTUS 1,900,000 Shares of Common Stock This prospectus relates to the proposed resale from time to time by Innovative Cellular Therapeutics Holdings Limited, a Cayman Island exempted company incorporated with limited liability (“ICT Holdings”), as the selling stockholder, of up to 1,900,000 shares of our comm |
|
| December 11, 2025 |
LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 (650) 695-0677 CORRESP LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 (650) 695-0677 December 11, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Lauren Hamill RE: Lyell Immunopharma, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-291970 Dear Ms. Hamil |
|
| December 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 5, 2025 |
As filed with the Securities and Exchange Commission on December 5, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on December 5, 2025 Registration No. |
|
| December 5, 2025 |
Calculation of Filing Fee Tables S-3 Lyell Immunopharma, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In |
|
| December 5, 2025 |
EX-4.5 Exhibit 4.5 CONFIDENTIAL EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT by and between LYELL IMMUNOPHARMA, INC. and INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LIMITED November 6, 2025 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of November 6, 2025 (the “Effective Date”), by and between Lyell Immunopharma, Inc., a Delaware c |
|
| December 5, 2025 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF LYELL IMMUNOPHARMA, INC. (A DELAWARE CORPORATION) June 21, 2021 (as amended December 3, 2025) Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Se |
|
| December 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 12, 2025 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 •Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colo |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| November 10, 2025 |
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR EX-99.1 Exhibit 99.1 Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer • LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrol |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 13, 2025 |
LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 CORRESP LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 VIA EDGAR August 13, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Lyell Immunopharma, Inc Registration Statement on Form S-3 File No. 333-289539 Acceleration Request Requested Date: August 15 |
|
| August 13, 2025 |
August 13, 2025 Lynn Seely President and Chief Executive Officer Lyell Immunopharma, Inc. |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| August 12, 2025 |
Calculation of Filing Fee Tables S-3 Lyell Immunopharma, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In |
|
| August 12, 2025 |
Offer Letter, by and between the Registrant and Mark Meltz, dated June 4, 2025 Exhibit 10.2 June 4, 2025 Mark Meltz Electronic delivery Re: Offer of Employment by Lyell Immunopharma, Inc. Dear Mark, I am very pleased to confirm our offer to you of employment as General Counsel at Lyell Immunopharma, Inc. (the “Company”). The opportunity to work with you to build one of the world’s great companies whose goal is nothing less than to develop curative therapies for cancer is one |
|
| August 12, 2025 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 •Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphoma •Initiated the PiNACLE pivotal trial of LYL314 in patients with large B-cell lymphoma receiving treatment in |
|
| August 12, 2025 |
As filed with the Securities and Exchange Commission on August 12, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 12, 2025 Registration No. |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 12, 2025 |
Offer Letter, by and between the Registrant and David R. Shook, dated June 3, 2025 Exhibit 10.1 June 3, 2025 David R, Shook, M.D. Electronic delivery Re: Offer of Employment by Lyell Immunopharma, Inc. Dear David, I am very pleased to confirm our offer to you of employment as Chief Medical Officer at Lyell Immunopharma, Inc. (the “Company”). The opportunity to work with you to build one of the world’s great companies whose goal is nothing less than to develop curative therapies |
|
| August 12, 2025 |
Form of Common Stock Certificate. Exhibit 4.1 NUMBER BB LI Lyell Lyell Immunopharma, Inc. LYELL IMMUNOPHARMA, INC. SHARES CUSIP 097702 10 4 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.00001 PAR VALUE PER SHARE, OF transferable on the books of the Corporation in person or by du |
|
| July 31, 2025 |
PROSPECTUS Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-288769 PROSPECTUS 625,000 Shares of Common Stock This prospectus relates to the proposed resale from time to time by the selling stockholders identified in this prospectus of up to 625,000 shares of our common stock, par value $0.0001 per share. The shares of common stock registered for resale pursuant to this prospectus |
|
| July 28, 2025 |
LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 (650) 695-0677 CORRESP LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 (650) 695-0677 July 28, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Alan Campbell RE: Lyell Immunopharma, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-288769 Dear Mr. Campbell: |
|
| July 25, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of July 24, 2025, is made by and among LYELL IMMUNOPHARMA, INC., a Delaware corporation (the “Company”), and the Purchasers listed on Exhibit A hereto, together with their permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS: A. The Company and the Purchase |
|
| July 25, 2025 |
Lyell Immunopharma Announces up to $100 Million Equity Private Placement EX-99.1 Exhibit 99.1 Lyell Immunopharma Announces up to $100 Million Equity Private Placement SOUTH SAN FRANCISCO, Calif., July 25, 2025 — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement with certain institutiona |
|
| July 25, 2025 |
Form of Pre-Funded Warrant to Purchase Common Stock EX-4.1 Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS, OR UNLESS OFFE |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 23, 2025 |
July 23, 2025 Lynn Seely President and Chief Executive Officer Lyell Immunopharma, Inc. |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 Table of Contents As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lyell Immunopharma, Inc. |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 28, 2025 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LYELL IMMUNOPHARMA, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Lyell Immunopharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”) |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 13, 2025 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 •Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell lymphoma at the 18th International Conference on Malignant Lymphoma. •Rece |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 21, 2025 |
' &%&&% %'$&% * ! %%! ).?56:4@;: 999999999999999999999999999999999 !$ 999999999999999999999999999999999 .>7!:2 ' $"!$&"'$%' &&!%&! !$ 1!&%'$&% * & ! ;>@5236?0.8E2.>2:1212029/2> ;> &$ %&! $"!$&"'$%' &&!%&! !$ 1!&%'$ &%* &! ;>@52@>.:?6@6;:<2>6; |
|
| April 21, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t |
|
| April 10, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of th |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 11, 2025 |
As filed with the Securities and Exchange Commission on March 11, 2025 As filed with the Securities and Exchange Commission on March 11, 2025 Registration No. |
|
| March 11, 2025 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-8 Lyell Immunopharma, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per share, reserved for issuance pursuant |
|
| March 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 11, 2025 |
Exhibit 10.22 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT This exclusive license agreement (“Agreement”) is made effective February 18, 2021 (“Effective Date”), by and between The Regents of the University of California, a California |
|
| March 11, 2025 |
yell Immunopharma, Inc. Insider Trading Exhibit 19.1 Lyell Immunopharma, Inc. Insider Trading Policy Adopted by the Board of Directors: April 19, 2021 Last Amended by the Board of Directors: December 11, 2024 Introduction During the course of your relationship with Lyell Immunopharma, Inc. (“Lyell”), you may receive material information that is not yet publicly available (“material nonpublic information”) about Lyell or other publicly t |
|
| March 11, 2025 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 •Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL) •Presented positive initial data from Phase 1 multi-cen |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-405 |
|
| February 14, 2025 |
Exhibit 1 AGREEMENT Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Lyell Immunopharma, Inc. |
|
| February 5, 2025 |
POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg and Brenda Schulz |
|
| February 5, 2025 |
EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 BlackRock Advisors, LLC BlackRock Asset Management Canada Limited BlackRock Fund Advisors BlackRock Asset Management Ireland Limited BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outstanding shares of the security class being re |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 10, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Inco |
|
| January 10, 2025 |
IMMPACT BIO USA, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 IMMPACT BIO USA, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Independent Auditor’s Report 2 Consolidated Balance Sheets 4 Consolidated Statement of Operations and Comprehensive Loss 5 Consolidated Statement of Convertible Preferred Stock and Stockholders’ Deficit 6 Consolidated Statement of Cash Flows 7 Notes to the Consolidated Financial Statements 8 1 Exhibit 99.1 INDEPENDE |
|
| January 10, 2025 |
Lyell Immunopharma, Inc. Unaudited Pro Forma Condensed Combined Financial Information Exhibit 99.3 Lyell Immunopharma, Inc. Unaudited Pro Forma Condensed Combined Financial Information Summary of Transaction On October 31, 2024 (the “Closing Date”), Lyell Immunopharma, Inc., a Delaware corporation (the “Company” or “Lyell”), completed its previously announced acquisition (the “Acquisition”) of ImmPACT Bio USA Inc., a Delaware corporation (“ImmPACT”), pursuant to the Agreement and P |
|
| January 10, 2025 |
IMMPACT BIO USA, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.2 IMMPACT BIO USA, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Financial Statements as of and for the Nine Months Ended September 30, 2024 PAGE Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statement of Operations and Comprehensive Loss 3 Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders’ Deficit 4 Cond |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 10, 2024 |
Lyell Presents Positive Initial Clinical Data from the Phase Exhibit 99.1 Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting • Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2 prior lines of therapy • Manag |
|
| December 9, 2024 |
PROSPECTUS Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-283533 PROSPECTUS 37,499,981 Shares of Common Stock This prospectus relates to the proposed resale from time to time by the selling stockholders identified in this prospectus of up to 37,499,981 shares of our common stock, par value $0.0001 per share. The shares of common stock registered for resale pursuant to this prospectus |
|
| December 3, 2024 |
December 3, 2024 Lynn Seely, M.D. President and Chief Executive Officer Lyell Immunopharma, Inc. 201 Haskins Way South San Francisco, California 94080 Re: Lyell Immunopharma, Inc. Registration Statement on Form S-3 Filed November 29, 2024 File No. 333-283533 Dear Lynn Seely M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules |
|
| December 3, 2024 |
LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 (650) 695-0677 LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 (650) 695-0677 December 3, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, NE Washington, D.C. 20549 Attn: Tim Buchmiller RE: Lyell Immunopharma, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-283533 Dear Mr. Buchmiller: P |
|
| November 29, 2024 |
Calculation of Filing Fee Tables Form S-3 (Form Type) Lyell Immunopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo |
|
| November 29, 2024 |
As filed with the Securities and Exchange Commission on November 29, 2024 As filed with the Securities and Exchange Commission on November 29, 2024 Registration No. |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 12, 2024 |
LYEL / Lyell Immunopharma, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 UnitedStates13GLyellImmun.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* (Name of Issuer) Lyell Immunopharma Inc (Title of Class of Se |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| November 7, 2024 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 •Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin’s lymphoma •Presenting initial data from Phase |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 4, 2024 |
LYEL / Lyell Immunopharma, Inc. / VANGUARD GROUP INC Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Lyell Immunopharma Inc (Title of Class of Securities) Common Stock (CUSIP Number) 550 |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 31, 2024 |
Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT by and among LYELL IMMUNOPHARMA, INC., EACH OF THE SELLERS PARTY HERETO and WT REPRESENTATIVE LLC, solely in its capacity as the Representative of the Sellers October 31, 2024 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of October 31, 2024, by and among Lyell Immunopharma, Inc., a Delawar |
|
| October 31, 2024 |
LYEL / Lyell Immunopharma, Inc. / Foresite Capital Fund IV, L.P. - SC 13G Passive Investment SC 13G 1 tm2427216d1sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Lyell Immunopharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 55083R104 (CUSI |
|
| October 31, 2024 |
Lyell Immunopharma Completes Acquisition of ImmPACT Bio Exhibit 99.1 Lyell Immunopharma Completes Acquisition of ImmPACT Bio • Acquisition strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal development in 2025 in patients in the 3rd line setting with B-cell non-Hodgkin lymphoma who have not yet been exposed to CAR T-cell therapy • Sumant Ramachandra, |
|
| October 24, 2024 |
Exhibit 99.1 Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies • Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate • Data from ImmPACT’s multi-center Phase 1-2 clinical trial of IMPT-314 in patients with large B-cell lymphoma treated in the 3rd line CAR-n |
|
| October 24, 2024 |
Exhibit 2.1 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AGREEMENT AND PLAN OF MERGER by and among IMMPACT BIO USA INC., LYELL IMMUNOPHARMA, INC., INSPIRE MERGER SUB INC. and WT REPRESENTATIVE LLC, solely in its capacity as the Representative October 24, 2024 Ta |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 7, 2024 |
Lyell Immunopharma, Inc. Non-Employee Director Compensation Policy. Exhibit 10.1 Lyell Immunopharma, Inc. Non-Employee Director Compensation Policy Adopted by the Board of Directors: November 11, 2019 Last Amended and Restated: April 24, 2024, to be effective June 14, 2024 Effective Date: June 14, 2024 Each member of the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) who is a non- employee director of the Company (each such member, an |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| August 7, 2024 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 •Reported dose-dependent antitumor clinical activity in patients with relapsed/refractory triple-negative breast cancer from the Phase 1 trial of LYL797, a ROR1-targeted Chimeric Antigen Receptor (CAR) T‑cell product candidate enhanced with proprietary anti-exhaustion technology; 40% objec |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 26, 2024 |
EX-99.2 Exhibit 99.2 Initial Clinical and Translational Data from Phase 1 Trial of LYL797, an Enhanced ROR1-targeted CAR-T Cell Product Candidate June 26, 2024 1 Forward Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Lyell Immunopharma, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Secu |
|
| June 26, 2024 |
EX-99.1 Exhibit 99.1 Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology • Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose clea |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 6, 2024 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 •Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarter •On track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the second h |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 6, 2024 |
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Reg. No. 333-277495 PROSPECTUS SUPPLEMENT (To prospectus dated May 3, 2024) $150,000,000 Common Stock We have entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC (TD Cowen), relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms |
|
| May 1, 2024 |
LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 VIA EDGAR May 1, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: Tamika Sheppard Re: Lyell Immunopharma, Inc. Registration Statement on Form S-3 File No. 333-277495 Acceleration Request Requested D |
|
| April 22, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def |
|
| April 22, 2024 |
' &%&&% %'$&% * ! %%! ).?56:4@;: 777777777777777777777777777777777 !$ 777777777777777777777777777777777 .>7!:2 ' $"!$&"'$%' &&!%&! !$ 1!&%'$&% * & ! ;>@5236?0.8E2.>2:1212029/2> ;> &$ %&! $"!$&"'$%' &&!%&! !$ 1!&%'$ &%* &! ;>@52@>.:?6@6;:<2>6; |
|
| March 4, 2024 |
United States securities and exchange commission logo March 4, 2024 Matthew Lang Chief Business Officer Lyell Immunopharma, Inc. |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 S-8 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 29, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.9 LYELL IMMUNOPHARMA, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF LYELL IMMUNOPHARMA, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and |
|
| February 29, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.8 LYELL IMMUNOPHARMA, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF LYELL IMMUNOPHARMA, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and |
|
| February 29, 2024 |
Sales Agreement dated February 28, 2024, among the Registrant and Cowen and Company, LLC Exhibit 1.2 LYELL IMMUNOPHARMA, INC. $150,000,000 SALES AGREEMENT February 28, 2024 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 29, 2024 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-8 Lyell Immunopharma, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per share, reserved for issuance pursuant |
|
| February 29, 2024 |
Exhibit 4.5 LYELL IMMUNOPHARMA, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20[•] Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lyell Immunopharma, Inc. |
|
| February 29, 2024 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.7 LYELL IMMUNOPHARMA, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF LYELL IMMUNOPHARMA, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-405 |
|
| February 28, 2024 |
Incentive Compensation Recoupment Policy dated September 6, 2023. Exhibit 97.1 Lyell Immunopharma, Inc. Incentive Compensation Recoupment Policy Adopted by the Compensation Committee of the Board of Directors: September 9, 2023 1.Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the C |
|
| February 28, 2024 |
ffer Letter by and between the Registrant and Gary Lee, dated Nove Exhibit 10.16 November 24, 2021 Gary Lee Electronic delivery Re: Offer of Employment by Lyell Immunopharma, Inc. Dear Gary: I am very pleased to confirm our offer to you of employment with Lyell Immunopharma, Inc. (the “Company”). The opportunity to work with you to build one of the world’s great companies whose goal is nothing less than to develop curative therapies for solid tumors is one I am t |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 28, 2024 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 •On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024 •Received Orphan Drug Designation for LYL845 for the treatment of melanoma •Expect to submit IND for second generation ROR1-targeted CAR T-cell product in the f |
|
| February 14, 2024 |
SC 13G/A 1 arch-sch13g18793.htm ARCH VENTURE FUND IX, L.P. - LYELL IMMUNOPHARMA - SCH 13G/A(#1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lyell Immunopharma, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 55083R 104 (CUSIP Number) December 31, 2023 |
|
| February 13, 2024 |
LYEL / Lyell Immunopharma, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01376-lyellimmunopharmainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Lyell Immunopharma Inc Title of Class of Securities: Common Stock CUSIP Number: 55083R104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to |
|
| January 29, 2024 |
LYEL / Lyell Immunopharma, Inc. / BlackRock Inc. Passive Investment SC 13G 1 us55083r1041012924.txt us55083r1041012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Lyell Immunopharma, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 55083R104 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 7, 2023 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023 •Extended funding of operations into 2027 by prioritizing investment in core clinical candidates and research platform value drivers as well as de-prioritizing selected early-stage research programs •Remain on track to release initial clinical data from two clinical-stage product candidates |
|
| November 7, 2023 |
Lyell Immunopharma, Inc. Non-Employee Director Compensation Policy. Exhibit 10.2 Lyell Immunopharma, Inc. Non-Employee Director Compensation Policy Adopted and Effective: November 11, 2019 Last Amended and Restated: September 6, 2023 Each member of the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) who is a non-employee director of the Company (each such member, an “Eligible Director”) will receive the compensation described in this N |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 7, 2023 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF LYELL IMMUNOPHARMA, INC. (A DELAWARE CORPORATION) June 21, 2021 (as amended November 3, 2023) Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS' MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings. 1 Section |
|
| November 7, 2023 |
Offer Letter by and between the Registrant and Matthew Lang, dated May 12, 2023. Exhibit 10.1 May 12, 2023 Matthew Lang Electronic delivery Re: Offer of Employment by Lyell Immunopharma, Inc. Dear Matt, I am very pleased to confirm our offer to you of employment as Chief Business Officer of Lyell Immunopharma, Inc. (the "Company"). The opportunity to work with you to build one of the world’s great companies whose goal is nothing less than to develop curative therapies for soli |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| September 11, 2023 |
EX-99.1 Exhibit 99.1 DRAFT JPM22 Updated 12-14-21 Lyell Immunopharma September 11, 2023 Forward-looking statements Certain matters discussed in this presentation are “forward-looking statements” of Lyell Immunopharma, Inc, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). All such written |
|
| September 11, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 8, 2023 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023 •Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestones •Remain on track for initial clinical data from two lead product candidates in 2024 •Further strengthened executive leadersh |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 8, 2023 |
effective June 24, 2023, by and among the Exhibit 10.1 RELEASE AND SEPARATION AGREEMENT This Release and Separation Agreement (this “Agreement”) is made and entered into by and between Lyell Immunopharma, Inc. (the “Company”), and the undersigned employee (“Employee”). All capitalized terms used in this Agreement that are not defined herein shall have the same respective meanings as set forth in the Lyell Immunopharma, Inc. Officer Severa |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Lyell Immunopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40502 83-1300510 (State or other jurisdiction of incorporation) (Commission F |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| May 4, 2023 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023 •Two phase 1 clinical trials recruiting patients at 14 sites across the US; nine sites for LYL797, a ROR-1-targeted chimeric antigen receptor T cell (CAR-T) product candidate, and five sites for LYL845, a tumor infiltrating lymphocyte (TIL) product candidate •Cash, cash equivalents and mark |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 28, 2023 |
' &%&&% %'$&% * ! %%! ).?56:4@;: 777777777777777777777777777777777 !$ 777777777777777777777777777777777 .>7!:2 ' $"!$&"'$%' &&!%&! !$ 1!&%'$&% * & ! ;>@5236?0.8E2.>2:1212029/2> ;> &$ %&! $"!$&"'$%' &&!%&! !$ 1!&%'$ &%* &! ;>@52@>.:?6@6;:<2> |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| April 27, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| February 28, 2023 |
Power of Attorney (included on the signature page of this registration statement). S-8 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 28, 2023 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description is a description of the common stock, $0.0001 par value per share (“Common Stock”) of Lyell Immunopharma, Inc. (the “Company,” “we,” “our”, or “us”) which is the only security of the Company registered pursuant to Section 12 of the Securities Exc |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 28, 2023 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022 •Cash, cash equivalents and marketable securities of $710.3 million as of December 31, 2022 supports advancing robust pipeline into 2026, through multiple clinical milestones •Phase 1 clinical trials initiated for two wholly-owned product candidates for the treatment of solid |
|
| February 28, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 Lyell Immunopharma, Inc. |
|
| February 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-405 |
|
| February 13, 2023 |
LYEL / Lyell Immunopharma, Inc. / Foresite Capital Fund IV, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236260d3sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Lyell Immunopharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 55083R104 |
|
| February 9, 2023 |
LYEL / Lyell Immunopharma, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Lyell Immunopharma Inc. Title of Class of Securities: Common Stock CUSIP Number: 55083R104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ |
|
| December 16, 2022 |
Offer Letter, by and between the Registrant and Lynn Seely, dated December 14, 2022 EXHIBIT 10.2 December 14, 2022 Lynn Seely, M.D. Electronic delivery Re: Offer of Employment by Lyell Immunopharma, Inc. Dear Lynn: I am very pleased to confirm our offer to you of employment as President and Chief Executive Officer (?CEO?) of Lyell Immunopharma, Inc. (the ?Company?). Your proposed start date as President and CEO is December 15, 2022 (the ?Effective Date?). You will be based out of |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 Lyell Immunopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40502 83-1300510 (State or other jurisdiction of incorporation) (Commiss |
|
| December 16, 2022 |
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer EXHIBIT 99.1 Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 ? Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Lynn Seely, MD, a member of the company?s board and former president and chi |
|
| December 16, 2022 |
EXHIBIT 10.1 SEPARATION, TRANSITION AND GENERAL RELEASE AGREEMENT THIS SEPARATION, TRANSITION AND GENERAL RELEASE AGREEMENT (the ?Agreement?) is entered into as of the last date on the signature page hereto by and between Lyell Immunopharma, Inc., a Delaware corporation (the ?Company?), and Liz Homans (?you?) (together, the ?Parties?). R E C I T A L S WHEREAS, you are employed by the Company in th |
|
| November 8, 2022 |
Offer Letter by and between the Registrant and Rahsaan Exhibit 10.2 September 12, 2022 Rahsaan W. Thompson Electronic delivery Re: Offer of Employment by Lyell Immunopharma, Inc. Dear Rahsaan: I am very pleased to confirm our offer to you of employment with Lyell Immunopharma, Inc. (the ?Company?). The opportunity to work with you to build one of the world?s great companies whose goal is nothing less than to develop curative therapies for solid tumors |
|
| November 8, 2022 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results ?Investigational New Drug (IND) application clearance of LYL845 advances second wholly owned product candidate into clinical development ?Cash, cash equivalents and marketable securities of $750.7 million as of September 30, 2022; extends funding into 2026 and supports advancement of multiple pro |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 24, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 6, 2022 |
Exhibit 99.1 Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors ? Autologous TIL therapy enhanced with Lyell?s Epi-R? reprogramming technology designed to create polyclonal T cell populations with properties of durable stemness and improved function ? Phase 1 trial to initially enrol |
|
| October 6, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 4, 2022 |
As filed with the Securities and Exchange Commission on August 4, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 4, 2022 Registration No. |
|
| August 4, 2022 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights ?Cash, cash equivalents and marketable securities of $787.0 million as of June 30, 2022 provides funding into 2025 and supports advancement of multiple product candidates through key clinical milestones SOUTH SAN FRANCISCO, Calif., August 4, 2022 - Lyell Immunopharma, Inc. (Lyell) (Nasdaq: LYEL), a cli |
|
| August 4, 2022 |
Exhibit 1.2 LYELL IMMUNOPHARMA, INC. Common Stock ($0.0001 par value) Having an Aggregate Offering Price of up to $200,000,000 Equity Distribution Agreement August 4, 2022 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 BofA Securities, Inc. One Bryant Park New York, NY 10036 Ladies and Gentlemen: Lyell Immunopharma, Inc., a Delaware corporation (the ?Company?) confirms its agreem |
|
| August 4, 2022 |
EX-FILING FEES 9 d336653dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lyell Immunopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Ag |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| August 4, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.7 LYELL IMMUNOPHARMA, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF LYELL IMMUNOPHARMA, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between LYELL IMMUNOPHARMA, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and |
|
| August 4, 2022 |
Exhibit 10.2 Lyell Immunopharma, Inc. Notice and Acceptance of Amendment to Stock Options (Extension of Options Exercise Period) August 4, 2022 Elizabeth Homans Dear Liz, I am pleased to inform you that the Compensation Committee of the Board of Directors of Lyell Immunopharma, Inc. (the ?Company?) approved an amendment to the stock options granted to you under the Company?s 2018 Equity Incentive |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 4, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.6 LYELL IMMUNOPHARMA, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF LYELL IMMUNOPHARMA, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between LYELL IMMUNOPHARMA, INC. a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing |
|
| August 4, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.8 LYELL IMMUNOPHARMA, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF LYELL IMMUNOPHARMA, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between LYELL IMMUNOPHARMA, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and |
|
| August 4, 2022 |
Exhibit 4.4 LYELL IMMUNOPHARMA, INC. AND , AS TRUSTEE FORM OF INDENTURE DATED AS OF Debt Securities LYELL IMMUNOPHARMA, INC. FORM OF INDENTURE THIS INDENTURE, dated as of [?], between LYELL IMMUNOPHARMA, INC., a Delaware corporation (the ?Company?), and [TRUSTEE], as trustee (the ?Trustee?): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of t |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 10, 2022 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights ?Cash, cash equivalents and marketable securities of $838 million as of March 31, 2022 supports advancing a robust cell therapy pipeline ?Research highlighting novel reprogramming technologies designed to overcome barriers to successful adoptive cell therapy in solid tumors presented at multiple scienti |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 10, 2022 |
Severance Waiver by and between the Registrant and Stephen Hill, dated April 19, 2022. Exhibit 10.1 CERTIFICATION PURSUANT TO SEVERANCE WAIVER THIS SEVERANCE WAIVER (the ?Agreement?) is made and entered into by and between Stephen Hill (?Executive?) and Lyell Immunopharma, Inc. (the ?Company?), effective as of April 19, 2022. Whereas, the Company and Executive previously entered into an offer of employment letter dated May 14, 2019 (the ?Offer Letter?), which governs the terms of Ex |
|
| April 28, 2022 |
DEF 14A 1 edge20001347x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 29, 2022 |
Lyell Immunopharma, Inc. Officer Severance Plan. Exhibit 10.8 LYELL IMMUNOPHARMA, INC. OFFICER SEVERANCE PLAN (As Amended and Restated February 11, 2022) The Lyell Immunopharma, Inc. Officer Severance Plan was established as of the Effective Date and is amended and restated effective as of February 11, 2022. The purpose of the Plan is to provide severance and/or accelerated vesting benefits to certain eligible employees of Lyell Immunopharma, In |
|
| March 29, 2022 |
Lyell Immunopharma, Inc. Unaudited Selected Consolidated Financial Data (in thousands) Exhibit 99.1 Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights ?Cash, cash equivalents and marketable securities of $898 million as of December 31, 2021 supports advancing multi-modality cell therapy pipeline ?Clinical development commencing for two programs that incorporate Lyell?s novel reprogramming technologies SOUTH SAN FRANCISCO, Calif., M |
|
| March 29, 2022 |
Exhibit 10.16 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Second Amendment to the Collaboration and License Agreement between Lyell Immunopharma, Inc. and GlaxoSmithKline Intellectual Property (No.5) Limited [*] This Second Amendment to the Collaboration and Li |
|
| March 29, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 Lyell Immunopharma, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per share, reserved for issuance pursuant |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-405 |
|
| March 29, 2022 |
As filed with the Securities and Exchange Commission on March 29, 2022 As filed with the Securities and Exchange Commission on March 29, 2022 Registration No. |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ???)* Lyell Immunopharma, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 55083R 104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
LYEL / Lyell Immunopharma, Inc. / NEWTON (PTC) Ltd - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LYELL IMMUNOPHARMA, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 55083R104 (CUSIP Number) DECEMBER 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2022 |
LYEL / Lyell Immunopharma, Inc. / MWG Management Ltd. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LYELL IMMUNOPHARMA, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 55083R104 (CUSIP Number) DECEMBER 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 11, 2022 |
LYEL / Lyell Immunopharma, Inc. / Foresite Capital Fund IV, L.P. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Lyell Immunopharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 55083R104 (CUSIP Number) December 31, 2021 (Date of |
|
| February 10, 2022 |
LYEL / Lyell Immunopharma, Inc. / GLAXOSMITHKLINE PLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 LYELL IMMUNOPHARMA, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) December 31, 2021 55083R 10 4 (CUSIP Number) (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| December 17, 2021 |
Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR Exhibit 99.2 Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid Tumors ? Expects to begin screening patients for the Phase 1 clinical trial by the end of the first quarter; initial data presentation expected in 2023 ? ROR1-targeted CAR T-cell therapy designed to overcome T-cell exhaustion and promote durab |
|
| December 17, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-3006753 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 17, 2021 |
Lyell Immunopharma Announces cGMP Qualification of LyFE Exhibit 99.1 Lyell Immunopharma Announces cGMP Qualification of LyFE? Manufacturing Center in Advance of Initiating Clinical Programs ? Lyell?s cGMP-compliant manufacturing facility, is designed to produce cell products at scale for upcoming clinical trials across its CAR, TIL and TCR programs ? LyFE Manufacturing Center integrates digital data analytics into processes for real-time production mon |
|
| December 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-3006753 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 12, 2021 |
Exhibit 99.1 Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights ? Cash and investments of $936.4 million as of September 30, 2021 supports advancing multi-modality cell therapy pipeline SOUTH SAN FRANCISCO, Calif., Nov 12, 2021 - Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-3006753 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2021 LYELL IMMUNOPHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 LYELL IMMUNOPHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of In |
|
| September 30, 2021 |
Dear Colleagues and Stockholders: Exhibit 99.1 Dear Colleagues and Stockholders: I am writing to let you know that I am taking a temporary medical leave of absence from Lyell as a result of a recent health situation. I expect to make a full recovery and to return in early 2022. I want to personally thank all Lyellites for the incredible work they are doing to advance the ambitious and important mission of Lyell. I?d also like to t |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 LYELL IMMUNOPHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-1300510 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40502 83-3006753 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40502 Lyell Immunopharma, Inc. |
|
| August 12, 2021 |
Exhibit 99.1 Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights ? Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trials ? Cash, cash equivalents and marketable securities of $974.8 million as of June 30, 2021 includes $391.8 million in net proceeds from initial public offering SOUTH SAN FRANCISCO, Ca |
|
| June 21, 2021 |
Exhibit 4.2 AMENDED AND RESTATED BYLAWS OF LYELL IMMUNOPHARMA, INC. (A DELAWARE CORPORATION) June 21, 2021 Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 6 Section 7 |
|
| June 21, 2021 |
Lyell Immunopharma, Inc. 2021 Equity Incentive Plan. Exhibit 99.3 LYELL IMMUNOPHARMA, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 8, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 15, 2021 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan?s Availab |
|
| June 21, 2021 |
As filed with the U.S. Securities and Exchange Commission on June 21, 2021 As filed with the U.S. Securities and Exchange Commission on June 21, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lyell Immunopharma, Inc. (Exact name of Registrant as specified in its charter) Delaware 83-1300510 (State or other jurisdiction of Incorporation or organization) (I. |
|
| June 21, 2021 |
Lyell Immunopharma, Inc. 2021 Employee Stock Purchase Plan. Exhibit 99.6 LYELL IMMUNOPHARMA, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 8, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 15, 2021 IPO DATE: JUNE 16, 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company |
|
| June 21, 2021 |
Amended and Restated Certificate of Incorporation. Exhibit 4.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LYELL IMMUNOPHARMA, INC. Lyell Immunopharma, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware (the ?DGCL?), hereby certifies that: ONE: The name of this corporation is Lyell Immunopharma, Inc. The date of filing the original Certificate of Incorporation of this |
|
| June 18, 2021 |
25,000,000 shares Common Stock 424B4 1 d168165d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-256470 25,000,000 shares Common Stock This is an initial public offering of shares of common stock of Lyell Immunopharma, Inc. We are offering 25,000,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price of |
|
| June 16, 2021 |
The Nasdaq Stock Market LLC, 805 King Farm Blvd., Rockville, MD 20850 Lisa Roberts Vice President Listing Qualifications June 16, 2021 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Division of Corporation Finance: This is to certify that on June 14, 2021 The Nasdaq Stock Market LLC (the "Exchange") received from Lyell Immunopharma |
|
| June 16, 2021 | ||
| June 14, 2021 |
June 14, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Thomas Kluck Laura Crotty Re: Lyell Immunopharma, Inc. Registration Statement on Form S-1, as amended (File No. 333-256470) Acceleration Request Requested Date: Wednesday, June 16, 2021 Requested Time: 4:00 P.M. Eastern Time Ladies |
|
| June 14, 2021 |
8-A12B 1 d152418d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Lyell Immunopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 83-1300510 (State of Incorporation or Organization) (I.R.S. Employer Ident |
|
| June 14, 2021 |
LYELL IMMUNOPHARMA, INC. 400 East Jamie Court, Suite 301 South San Francisco, California 94080 LYELL IMMUNOPHARMA, INC. 400 East Jamie Court, Suite 301 South San Francisco, California 94080 June 14, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Thomas Kluck and Laura Crotty Re: Lyell Immunopharma, Inc. Registration Statement on Form S-1, as amended (File No. 333-256470) Request for Acceleration of Effec |
|
| June 9, 2021 |
Table of Contents As filed with to the Securities and Exchange Commission on June 9, 2021. |
|
| June 9, 2021 |
Lyell Immunopharma, Inc. 2021 Equity Incentive Plan. Exhibit 10.3 LYELL IMMUNOPHARMA, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE [], 2021 APPROVED BY THE STOCKHOLDERS: JUNE [], 2021 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan?s Availa |
|
| June 9, 2021 |
Form of Amended and Restated Bylaws, to be in effect immediately after the closing of the offering. Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF LYELL IMMUNOPHARMA, INC. (A DELAWARE CORPORATION) June [?], 2021 Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 6 Section |
|
| June 9, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 Lyell Immunopharma, Inc. Common Stock Underwriting Agreement , 2021 Goldman Sachs & Co. LLC BofA Securities, Inc. J.P. Morgan Securities LLC Morgan Stanley & Co. LLC As representatives (the ?Representatives?) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street New York, NY 10282-2198 c/o BofA Securities, Inc. One Bryant Park New York, NY |
|
| June 9, 2021 |
Exhibit 10.5 LYELL IMMUNOPHARMA, INC. GLOBAL RSU AWARD GRANT NOTICE (2021 EQUITY INCENTIVE PLAN) Lyell Immunopharma, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company?s 2021 Equity Incentive |
|
| June 9, 2021 |
Form of Common Stock Certificate. Exhibit 4.1 NUMBER BB LI Lyell Lyell Immunopharma, Inc. LYELL IMMUNOPHARMA, INC. SHARES CUSIP 097702 10 4 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.00001 PAR VALUE PER SHARE, OF transferable on the books of the Corporation in person or by du |
|
| June 9, 2021 |
Lyell Immunopharma, Inc. 2021 Employee Stock Purchase Plan. Exhibit 10.6 LYELL IMMUNOPHARMA, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE [], 2021 APPROVED BY THE STOCKHOLDERS: JUNE [], 2021 IPO DATE: JUNE [], 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company |
|
| June 9, 2021 |
Lyell Immunopharma, Inc. 2021 Non-Employee Director Compensation Policy. Exhibit 10.7 Lyell Immunopharma, Inc. Non-Employee Director Compensation Policy Adopted and Effective: November 11, 2019 Amended and Restated Effective: [], 2021 Each member of the Board of Directors (the ?Board?) of Lyell Immunopharma, Inc. (the ?Company?) who is a non-employee director of the Company (each such member, an ?Eligible Director?) will receive the compensation described in this Non-E |
|
| June 9, 2021 |
Exhibit 10.4 LYELL IMMUNOPHARMA, INC. GLOBAL STOCK OPTION GRANT NOTICE (2021 EQUITY INCENTIVE PLAN) Lyell Immunopharma, Inc. (the ?Company?), pursuant to its 2021 Equity Incentive Plan (the ?Plan?), has granted to you (?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms and conditions as set forth |
|
| June 9, 2021 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LYELL IMMUNOPHARMA, INC. Lyell Immunopharma, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware (the ?DGCL?), hereby certifies that: ONE: The name of this corporation is Lyell Immunopharma, Inc. The date of filing the original Certificate of Incorporation of this |
|
| June 9, 2021 |
Exhibit 10.15 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT BETWEEN Lyell Immunopharma, Inc. AND GlaxoSmithKline Intellectual Property (No. 5) Limited [*] May 23, 2019 CONFIDENTIAL EXECUTION VERSION Table of Contents 1. DEFINIT |
|
| June 7, 2021 |
David G. Peinsipp +1 415 693 2177 [email protected] June 7, 2021 Via EDGAR and Email U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Vanessa Robertson Jenn Do Thomas Kluck Laura Crotty Re: Lyell Immunopharma, Inc. Registration Statement on Form S-1 Filed May 25, 2021 File No. 333-256470 Ladies and Ge |
|
| June 4, 2021 |
United States securities and exchange commission logo June 4, 2021 Heather Turner Chief General Counsel Lyell Immunopharma, Inc. |
|
| June 1, 2021 |
David G. Peinsipp +1 415 693 2177 [email protected] CONFIDENTIAL TREATMENT REQUESTED BY LYELL IMMUNOPHARMA, INC. June 1, 2021 CERTAIN PORTIONS OF THIS LETTER HAVE BEEN OMITTED FROM THE VERSION SUBMITTED VIA EDGAR. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. INFORMATION THAT WAS OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS LETTER WITH A PLACEHOLDER IDEN |
|
| May 28, 2021 |
May 28, 2021 Heather Turner Chief General Counsel Lyell Immunopharma, Inc. 400 East Jamie Court, Suite 301 South San Francisco, California 94080 Re: Lyell Immunopharma, Inc. Draft Registration Statement on Form S-1 Exhibit Nos. 10.15 and 10.16 Submitted April 12, 2021 CIK No. 0001806952 Dear Ms. Turner: You have redacted information from the exhibits identified above asserting that the redacted in |
